No improvement on second-line treatment with tisagenlecleucel in patients with DLBCL
Patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to first-line therapy or relapse within one year following first-line therapy have a poor prognosis. Presented by Michael Bishop, this MEDtalk summarize the results of the BELINDA trial. The trial randomizes patients in two arms to investigate effects of tisagenlecleucel, a CD19-directed CAR T-cell therapy, as second-line treatment. Unfortunately, BELINDA did not meet its primary end point, as second-line tisagenlecleucel did not improve event-free survival (EFS) compared with standard of care (SOC). However, more learnings to help design further trials in patients were derived from the trial.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.